Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00506142 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma
A Phase 2 study, sponsored by Spectrum Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
NCT00506142 is a Phase 2 study that has completed, run by Spectrum Pharmaceuticals. The registered enrollment target is 54 participants.
The verdict
NCT00506142, a Phase 2 study, has completed, sponsored by Spectrum Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
Study Summary
Marqibo (liposomal vincristine) is a form of vincristine preparation. Vincristine is designed to interfere with the multiplication of cancer cells, which may slow or stop their growing and spreading throughout the body. This may cause the cancer cells to die. Liposomal vincristine is formed when vincristine is placed inside of oil droplets called liposomes, which may help to improve the delivery of drug to the tumor site. The liposomal formulation results in a slow, steady release of vincristine in the tumor metastasis, exposing the cancer cells to vincristine continuously. The goal of this clinical research study is to learn if Marqibo (liposomal vincristine) can help to control metastatic uveal melanoma. The safety of liposomal vincristine will also be studied. Approximately 50 patients will take part in this study.
Interventions
- DRUG Marqibo® (vincristine sulfate liposomes injection)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2007-11 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00506142
The ClinicalTrials.gov registry entry for NCT00506142 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spectrum Pharmaceuticals, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Marqibo® (vincristine sulfate liposomes injection) is the first listed.
NCT00506142 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00506142 about?
NCT00506142 is a clinical study titled "Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma". Marqibo (liposomal vincristine) is a form of vincristine preparation. Vincristine is designed to interfere with the multiplication of cancer cells, which may slow or stop their growing and spreading throughout the body. This may cause the cancer cells to die. Liposomal vincristine is formed when vin...
What is the current status of trial NCT00506142?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2007-11. Estimated completion is 2014-12.
What interventions are being tested in trial NCT00506142?
The interventions under investigation include: Marqibo® (vincristine sulfate liposomes injection) (DRUG).
Who is sponsoring clinical trial NCT00506142?
This trial is sponsored by Spectrum Pharmaceuticals, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.